Parexel International Corp (PRXL) Files Form 4 Insider Selling : Eduard E. Holdener Sells 700 Shares

Parexel International Corp (PRXL): Eduard E. Holdener , director of Parexel International Corp sold 700 shares on Jun 2, 2016. The Insider selling transaction was reported by the company on Jun 3, 2016 to the Securities and Exchange Commission. The shares were sold at $62.98 per share for a total value of $44,086.00 , the company said in a SEC Form 4 Filing.

Other Insider transactions have been reported by the company according to SEC Form 4, on May 26, 2016, Ulf I Schneider (SVP & Chief Admin. Officer) sold 7,500 shares at $62.00 per share price.On Mar 3, 2016, Christopher J Lindop (director) sold 2,000 shares at $60.28 per share price.Also, On Dec 2, 2015, Richard L Love (director) sold 1,330 shares at $68.21 per share price.On Nov 24, 2015, Eduard E. Holdener (director) sold 2,200 shares at $67.66 per share price.

Shares of PAREXEL International Corporation (PRXL) ended Friday, Jun 3, 2016 session in red amid volatile trading. The shares closed down -1.65 points or -2.56% at $62.78 with 3,35,780 shares getting traded. Post opening the session at $64.25, the shares hit an intraday low of $62.48 and an intraday high of $64.25 and the price vacillated in this range throughout the day. The company has a market cap of $3,320 M and the number of outstanding shares has been calculated to be 5,28,87,809 shares. The 52-week high of PAREXEL International Corporation is $76.17 and the 52-week low is $56.

PAREXEL International Corporation Money Flow Index Chart

Company has been under the radar of several Street Analysts.PAREXEL International Corporation is Upgraded by Sun Trust Rbsn Humphrey to Buy. Earlier the firm had a rating of Neutral on the company shares. The Rating was issued on Mar 28, 2016.

PAREXEL International Corporation (PAREXEL) is a biopharmaceutical outsourcing services company which provides a range of expertise in clinical research clinical logistics medical communications consulting commercialization and advanced technology products and services to the pharmaceutical biotechnology and medical device industries across the world. The Company operates through three segments: Clinical Research Services PAREXEL Consulting Services and PAREXEL Informatics. Its product and service offerings include clinical trials management data management epidemiology health economics/outcomes research pharmacovigilance medical communications clinical pharmacology patient recruitment clinical supply and drug logistics post-marketing surveillance medical imaging services electronic data capture systems clinical trial management systems Web-based portals and other product development tools and services.

Leave a Reply

PAREXEL International Corporation - Is it time to Sell?

Top Brokerage Firms are advising their investors on PAREXEL International Corporation. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.